COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 470
[187] Schrag A, et al. Clinical, imaging, and laboratory features in
VGKC complex/LGI1 antibody-associated limbic encephalitis.
Neurol Clin Pract. 2016;6(6):494-501.
[188] European Journal of Medical Research. Prediction of clinical
progression in nervous system diseases: plasma glial fibrillary acidic
protein (GFAP). European Journal of Medical Research. 2023.
[189] Vojdani A. Antibodies as predictors of autoimmunity and
neuroinflammation. Autoimmune Dis. 2014;2014:347602.
[190] Biomedcentral. Prediction of clinical progression in nervous
system diseases: plasma glial fibrillary acidic protein (GFAP).
European Journal of Medical Research. 2023;1-15.
[191] Beersheba D, et al. Treatment of autoimmune encephalitis:
first-line therapy and escalation protocols. Neurotherapeutics.
2021;18(1):126-142.
[192] Frontiers in Neurology. Blood Level of Glial Fibrillary Acidic
Protein (GFAP) Does not Correlate With Disease Progression in a
Rat Model of Familial ALS (SOD1G93A Transgenic). Frontiers in
Neurology. 2018;9:954.
[193] Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J
Med. 2018;378(9):840-851.
[194] PMC. Blood Level of Glial Fibrillary Acidic Protein (GFAP) Does
not Correlate With Disease Progression in a Rat Model of Familial
ALS (SOD1G93A Transgenic). PMC. 2018.
[195] Khandaker GM, et al. Inflammation and immunity in
schizophrenia: implications for pathophysiology and treatment.
Lancet Psychiatry. 2015;2(3):258-270.
[196] Rose NR. Prediction and prevention of autoimmune disease:
the paradigm shift. Autoimmun Rev. 2012;12(5):659-661.
470
